

Journal of Visualized Experiments

Human serum anti-aquaporin-4 immunoglobulin G detection by cell-based assay --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59014R1
Full Title:	Human serum anti-aquaporin-4 immunoglobulin G detection by cell-based assay
Keywords:	Aquaporin-4; immunoglobulin G; cell-based assay; neuromyelitis optica spectrum disorders; human; serum
Corresponding Author:	Ying Wang Jilin University First Hospital Changchun, Jilin CHINA
Corresponding Author's Institution:	Jilin University First Hospital
Corresponding Author E-Mail:	ying.wang@ki.se;yingwangki@outlook.com
Order of Authors:	Caiyun Liu Mingqin Zhu Ying Wang
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Beijing, China

TITLE:

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

AUTHORS & AFFILIATIONS:

Caiyun Liu¹, Mingqin Zhu¹, Ying Wang¹

¹Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China

Corresponding Author:

Ying Wang (yingwangki@outlook.com)

Tel: (46)-0790297839

Email Addresses of Co-authors:

Caiyun Liu (caiyun_0770@163.com)

Mingqin Zhu (mingqin.zhu@hotmail.com)

KEYWORDS:

Aquaporin-4, immunoglobulin G, cell-based assay, neuromyelitis optica spectrum disorders, human, serum

SUMMARY:

A cell-based assay is a widely used method to detect serum anti-aquaporin-4 immunoglobulin G. This method can be applied to clinical diagnosis and research studies of neuromyelitis optical spectrum disorders.

ABSTRACT:

Anti-aquaporin-4 (AQP4) immunoglobulin G (IgG) is the core diagnostic biomarker for neuromyelitis optica spectrum disorders (NMOSD). The cell-based assay (CBA) is a widely used method to detect anti-AQP4 IgG in human serum with high sensitivity and specificity. Briefly, serum anti-AQP4 IgG is captured by AQP4-transfected cell that is fixed on the biochip then detected by a fluorescein-labelled secondary antibody. Fluorescence microscopy is utilized to visualize the fluorescence, and the intensity of fluorescence is evaluated by at least two experienced clinicians. A final diagnosis of NMOSD can be made based on the combination of anti-AQP4 IgG detection results, clinical manifestations, and neuroradiological findings. According to previous studies, CBA is more sensitive and specific than other anti-AQP4 IgG detection methods, and it can be applied to both clinical diagnosis and studies of NMOSD. The method has limitations; for example, an international scale to evaluate serum anti-AQP4 IgG titers is still lacking. Here, a detailed protocol for human serum anti-AQP4 IgG detection using CBA is described.

INTRODUCTION:

Serum AQP4 IgG is a core diagnostic biomarker for neuromyelitis optica spectrum disorders (NMOSD)¹. The cell-based assay (CBA) is a widely used anti-AQP4 IgG detection method with high sensitivity and specificity. Here, a detailed protocol for CBA is introduced.

AQP4, a water channel protein, has six membrane-spanning units and two helical domains surrounding one aqueous pore². Anti-AQP4 IgG is involved in the pathogenesis of NMOSD through binding to its target AQP4, which is mainly located on the endfeet of astrocytes³. It has been shown that anti-AQP4 IgG is positive in approximately two-thirds of NMOSD patients⁴. In the most recent international diagnostic criteria for NMOSD, anti-AQP4 IgG is considered to be a core diagnostic biomarker⁵. In this regard, it is crucial to establish a reliable protocol to detect human serum anti-AQP4 IgG and facilitate clinical diagnosis of NMOSD.

Currently, various anti-AQP4 IgG detection methods are available, such as CBA, tissue-based assay, enzyme-linked immunosorbent assay, and flow cytometry^{6,7}. CBA employs EU90 cells, which are transfected with human AQP4, to capture anti-AQP4 IgG. The captured anti-AQP4 IgG is detected by fluorescent secondary antibodies and subsequently visualized by microscopy. Accumulating evidence has shown that CBA is more sensitive and specific than other anti-AQP4 IgG detection methods^{6,7}. According to a meta-analysis, the sensitivity and specificity of CBA were shown to be 76% and 99%, which were higher than tissue-based and enzyme-linked immunosorbent assays⁶. Furthermore, a multicenter comparison of diagnostic assays of anti-AQP4 IgG was conducted⁷. A total of 193 study subjects from 15 European diagnostic centers were enrolled⁷. Four different methods were utilized to detect serum anti-AQP4 IgG⁷. It was demonstrated that CBA was more sensitive and specific than the other methods⁷. As AQP4 is expressed as two major isoforms (AQP4-M1 and AQP4-M23), anti-AQP4 IgG capture cell is transfected with either AQP4-M1 or AQP4-M23. However, which type of capture cell is better remains controversial. One investigation has supported AQP4-M1 based CBA⁸, while others have indicated that AQP4-M23 based CBA is better^{7,9,10}. However, AQP4-M23-based CBA may yield false positive results due to unspecific IgG binding⁸. Jarius et al.¹¹ reported that there was no significant difference in anti-AQP4 IgG detection rates between AQP4-M1 and AQP4-M23-based CBAs.

In summary, serum anti-AQP4 IgG is a core biomarker for NMOSD. CBA has higher specificity and sensitivity than other anti-AQP4 IgG detection methods. It remains controversial whether AQP4-M1- or AQP4-M23-based CBA is better. In this article, a detailed protocol for AQP4-M1-based CBA is described, which can apply to clinical diagnosis and studies of NMOSD.

PROTOCOL:

This procedure was approved by the Ethics Committee of the First Hospital of Jilin University and was performed on approximately 1,500 subjects.

1. Patient Enrollment and Blood Sample Collection

1.1. Apply the laboratory detection of serum anti-AQP4 IgG to clinic patients with the chief complaints and symptoms listed below. Perform physical examination as well.

Optic neuritis: Patients suffer with visual deficits, such as loss of visual fields and reduction of

visual acuity.

Acute myelitis: Patients may present with paralysis, sensory deficits and autonomic dysfunction.

Area postrema syndrome: Patients may have symptoms of unexplained hiccups, nausea or vomiting.

Acute brainstem syndrome: Brainstem lesions could result in different symptoms and physical signs depending on the location of the lesions.

Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions.

Symptomatic cerebral syndrome with NMOSD-typical brain lesions.

NOTE: According to the international consensus diagnostic criteria for NMOSD⁵, a diagnosis of NMOSD can be made if the patient is serum anti-AQP4 IgG-positive and has at least one of the core clinical characteristics mentioned above. However, we do not recommend testing of anti-AQP4 IgG in patients with optic neuritis only.

1.2. Blood sample collection

NOTE: Patients do not need to be fasting.

1.2.1. Draw 2-3 mL of venous blood in a 4 mL vacuum blood collection tube.

1.2.2. Allow the serum to clot for 30 min at room temperature (RT).

NOTE: Prolonged clotting can increase serum levels due to leakage from platelets.

1.2.3. Centrifuge at 2100 x g for 5 min. Carefully transfer the serum to a new tube.

1.2.4. Analyze the serum immediately or aliquot and store at -20 or -80 °C.

NOTE: Storage at -20 °C is for storage of months, while -80 °C is for storage of years.

2. Anti-AQP4 Antibody Detection

CAUTION: Patient samples and used kit reagents should be considered infectious materials. Sodium azide-containing reagents in the kit are toxic. A flow chart of the protocol is provided in **Figure 1**.

2.1. Preparation

2.1.1. Bring the kit to RT before use.

NOTE: Store the kit at 2–8 °C.

2.1.2. Prepare at least 200 mL of PBS wash buffer containing 0.2% Tween 20. Pour 100 mL of

wash buffer into a 500 mL beaker.

2.1.3. Dilute the serum samples 10x with wash buffer. Prepare the positive and negative controls according to the instructions of the distributor.

2.2. Sample incubation

2.2.1. Add 30 μ L of the pre-diluted samples, positive control, or negative control to the reaction fields of the reagent tray (**Figure 2**).

NOTE: Avoid air bubbles.

2.2.2. Remove the protective cover on the biochip slides.

NOTE: Do not touch the biochips to avoid the detachment and contamination of fixed cells. Hold the slide side-by-side before removing the cover.

2.2.3. Apply the biochip slide to the reagent tray (**Figure 2**). Start a 30 min incubation at RT.

NOTE: Every sample should be an individual droplet connected to the corresponding biochip without mixing with other droplets.

2.2.4. Gently rinse the biochip slide once with wash buffer. Immerse the biochip slide into the 500 mL beaker filled with 100 mL of wash buffer for at least 5 min. Place the beaker on a shaker if possible.

2.2.5. Take out the biochip slide from the wash buffer. Carefully wipe away the residual wash buffer outside of the reaction fields with a paper towel. Expose the biochip slide in open air for 1–2 min to evaporate the residual wash buffer on the reaction field.

NOTE: Do not dry out the reaction fields. Do not touch the biochips with paper towel.

2.3. Secondary antibody incubation

2.3.1. Prepare the secondary antibody solution according to the instructions of the distributor.

2.3.2. Add 25 μ L of fluorescent secondary antibody to the reaction fields of a clean reagent tray.

2.3.3. Apply the biochip slide to the reagent tray loaded with secondary antibody. Incubate for 30 min at RT.

2.4. Mounting

2.4.1. Pour out the used wash buffer and add 100 mL of fresh wash buffer into the beaker. Repeat

the washing as described in steps 2.2.4 and 2.2.5.

2.4.2. Carefully add embedding medium to the reaction fields on a biochip slide (one drop per reaction field). Seal the biochip slide with one piece of cover glass. Avoid air bubbles.

2.5. Fluorescence detection

2.5.1. Turn on the fluorescent lamp of microscope and pre-heat for 15 min. Choose a 488 nm filter.

2.5.2. Open photograph software. Take pictures from both transfected and untransfected areas of all reaction fields with different magnifications. First, take one picture with 4X magnification for an overview, then take more pictures with 10X and 20X magnifications.

NOTE: The detailed protocol is shown in **Table 1**. Interpretation of the results is discussed in the representative results section.

3. Diagnosis of Patients

3.1. If the patient is serum anti-AQP4 IgG-positive and shows at least one core clinical characteristic of NMOSD (see discussion section), diagnose the patient with NMSOD⁵. However, if the patient is anti-AQP4 IgG-negative, a diagnosis of NMOSD may not be excluded.

REPRESENTATIVE RESULTS:

Using the procedure described here, specific anti-AQP4 IgG in serum is detectable. During the procedure, pre-diluted samples, a positive control, and a negative control were added to the reaction fields, which contain transfected and untransfected areas (**Figure 2**). Fluorescence of the negative control in a transfected area mainly indicated the unspecific binding of secondary antibody to the transfected cells on biochips (**Figure 3**). Homogeneously weak fluorescence was visible (**Figure 3**). As for the positive control, anti-AQP4 antibody was added to the reaction field. Strong fluorescence was observed in the transfected area, which indicated the specific binding of anti-AQP4 IgG to AQP4-M1 in the transfected cells (**Figure 4**). Fluorescence of the positive control in an untransfected area showed hints of unspecific binding of anti-AQP4 IgG to fixed cells on biochips (**Figure 4**). For 10x diluted samples, anti-AQP4 IgG-negative serum showed a fluorescent pattern similar to the negative control, while the positive serum showed a pattern similar to the positive control (**Figure 5**). The intensity of fluorescence was associated with the anti-AQP4 IgG titer. Examples of different intensity of fluorescence are presented in **Figure 5**. **Figure 5A,B** were from anti-AQP4 IgG-negative samples, while **Figure 5C–H** were from anti-AQP4 IgG-positive samples. As long as heterogeneous and granular fluorescence appeared in transfected areas, the sample was considered anti-AQP4 IgG-positive, regardless of the strength of the fluorescence. The diagnostic criteria for NMOSD, which is based on the serum anti-AQP4 IgG, will be further described in the discussion section.

In a few samples, only a small number of cells was strongly stained in transfected areas, and it was hard to determine whether the serum was anti-AQP4 IgG-positive or negative (**Figure 6**). In this case, “probable positive” can be reported. In rarer cases, the fluorescence of a sample in transfected areas was homogeneously stronger than in untransfected areas (**Figure 7**). In this case, the sample should be regarded as anti-AQP4 IgG-negative. The high intensity of background fluorescence might be nonspecific. To create a reliable report, all photographs should be blindly evaluated by at least two clinicians. The clinicians should be trained before evaluation. In this protocol, they were shown representative photographs of different sample types and were informed as to how to evaluate results. Then, they evaluated photographs together with an experienced clinician. Finally, the trained clinicians worked independently. In an ideal situation, it should be always the same clinicians who evaluate results.

FIGURE AND TABLE LEGENDS:

Figure 1: Flow chart of anti-AQP4 IgG detection protocol. AQP4-M1-transfected or untransfected EU 90 cells are fixed on the biochips. When adding serum to biochips, anti-AQP4 IgG in serum is captured by the fixed transfected cells. Then, fluorescein-labelled secondary antibody is applied to detect anti-AQP4 IgG. The fluorescence can be visualized by microscopy with various magnifications.

Figure 2: Sample incubation. (A) Top view of reagent tray. Every reagent tray contains five individual reaction fields. The positive control, samples, and negative control should be added to the separate reaction fields. **(B)** Top view of biochip slide. Every biochip slide contains five reaction fields, which have two subsections. The transfected subsection contains fixed AQP4-M1-transfected cells, while the untransfected subsection contains untransfected cells. **(C)** Front view of reagent tray and biochip slide. Reaction fields on the reagent tray and biochip slide are paired with each other. The sample added to the reaction field on reagent tray should be connected to the corresponding reaction field on the biochip slide.

Figure 3: Representative figures for negative control. (A) An overview of the transfected area of the negative control was obtained by 4X magnification microscopy. Homogeneously weak fluorescence was observed throughout the area. **(B,C)** More details were observed in 10X **(B)** and 20X **(C)** magnification photographs. Generally, the cell membrane and plasma were slightly stained, and the cell nucleus was unstained.

Figure 4: Representative figures for positive control. (A,B) Transfected **(A)** and untransfected **(B)** areas of positive control are shown. Homogeneously weak fluorescence was observed in untransfected areas, indicating unspecific binding of anti-AQP4 IgG to fixed cells. Conversely, heterogeneous strong fluorescence was observed in transfected areas, indicating specific binding of anti-AQP4 IgG to AQP4-M1 expressed on fixed cells. **(C–F)** More details of transfected **(C,E)** and untransfected **(D,F)** areas are observed in with 10X **(C, D)** or 20X **(E,F)** magnification. Weak and even fluorescence appeared in untransfected areas. However, a large percentage of cells in transfected areas showed intense fluorescence. In the plasma of strongly stained cells, anti-AQP4 IgG showed smooth and granular fluorescence. The cell nucleus was unstained or slightly stained.

Figure 5: Representative figures for anti-AQP4 antibody negative or positive samples. Samples were 10x diluted, and all figures shown were taken with a 10x objective. **(A,B)** Negative fluorescence sample: the fluorescence was homogeneously weak in both **(A)** transfected and **(B)** untransfected areas. **(C,D)** Weak fluorescence sample: when compared with untransfected areas **(D)**, a small amount of cells (approximately 25% to 50%) in transfected areas **(C)** showed more intense fluorescence. **(E,F)** Moderate fluorescence sample: in transfected areas **(E)**, strong granular fluorescence was observed in a medium amount of cells (approximately 50% to 75%). **(G,H)** Strong fluorescence sample: cells in untransfected areas **(H)** were weakly stained. However, in transfected areas **(G)**, granular fluorescence with high intensity appeared in a large number of cells (approximately over 75%). Generally, as the titer of anti-AQP4 IgG increased, both fluorescence intensity and percentage of strongly stained cells elevated correspondingly. The fluorescence of untransfected areas was always homogeneously weak.

Figure 6: Representative figures for anti-AQP4 antibody “probable positive” samples. **(A,B)** No significant differences in fluorescence patterns were observed between transfected **(A)** and untransfected **(B)** areas at 4x magnification. **(C–E)** With 10X **(C,D)** or 20X **(E,F)** magnification, a few cells in transfected areas **(C,E)** showed strong granular fluorescence.

Figure 7: Example of untypical anti-AQP4 IgG-negative sample. Both transfected **(A)** and untransfected **(B)** areas were homogeneously stained. However, the fluorescence in transfected areas was stronger than in untransfected areas.

Table 1: Fluorescence microscopy. It is recommended to use 4X, 10X, and 20X objectives for imaging of transfected and untransfected areas.

DISCUSSION:

We have described a widely accessible method to detect anti-AQP4 IgG in human serum. Anti-AQP4 IgG is closely related to NMOSD, and establishing a reliable anti-AQP4 IgG detection method is crucial for the clinical diagnosis of NMOSD. First, anti-AQP4 IgG is specific for NMOSD. Multiple sclerosis is also an immune-mediated disease of the central nervous system and shares many similarities with NMOSD¹². However, anti-AQP4 IgG is only positive in NMOSD¹³. Second, anti-AQP4 IgG is common among NMOSD patients. Approximately two-thirds of NMOSD patients are serum anti-AQP4 IgG-positive⁴. Third, the most recent diagnosis criteria for NMOSD is based on serum anti-AQP4 IgG testing⁵. Taken together, serum anti-AQP4 IgG detection could facilitate the clinical diagnosis of NMOSD.

Among various anti-AQP4 IgG detection methods, CBA is widely used for clinical diagnosis due to its high sensitivity and specificity^{6,7}. Although CBA is a quick and straightforward method, some key points should be addressed. First, experimenters should be careful when working with biochips, as AQP4-M1-transfected and untransfected cells are fixed on the biochips. During the whole procedure, biochips should not be touched by hand or dried out. Additionally, slides with biochips should be handled gently, otherwise the fixed cells on the biochips may fall down or become contaminated, which may result in fluorescence defective zones or a high fluorescent background. Second, when adding samples to the reaction fields on the reagent tray, researchers

must ensure that the drops of samples are not mixed with each other. Air bubbles between the samples and biochips should be avoided.

This method has limitations; for example, when using CBA to detect anti-AQP4 IgG, it is hard to quantify fluorescence intensity and describe the anti-AQP4 IgG titer in the serum. Currently, in our diagnostic center, the intensity of fluorescence is subjectively reported by two clinicians after comparing photographs of samples vs. controls. In most cases, it is not hard to determine whether the serum is anti-AQP4 IgG-positive or negative. However, in rare cases, the fluorescence from samples may seem only slightly stronger than the negative control, and the sample is considered to be “probable positive”. In this situation, clinicians should be more careful in making a diagnosis. Another possible solution is repeating the CBA. A more accurate method to quantify the intensity of fluorescence and an international definition of “anti-AQP4 IgG-positive” are warranted. Notably, the positive rate of anti-AQP4 IgG in cerebrospinal fluid is much lower than in serum, and testing for anti-AQP4 IgG in cerebrospinal fluid is not informative^{14,15}.

CBA can be applied to both clinical diagnosis and scientific studies of NMOSD. Clinical diagnosis of NMOSD is made based on the combination of clinical manifestations, serum anti-AQP4 IgG, and neuroradiological findings. Serum anti-AQP4 IgG-positive patients with at least one core clinical characteristic of NMOSD can be diagnosed with NMOSD⁵; however, if the patient is anti-AQP4 IgG-negative, a diagnosis of NMOSD should not be excluded⁵, and clinicians should further evaluate the clinical manifestations and neuroradiological findings^{5,16,17}. Serum myelin oligodendrocyte glycoprotein antibody may be detected to assist the diagnosis¹⁸⁻²⁰. Notably, although the serum anti-AQP4 IgG titer may be changed with rituximab treatment²¹, it is not predictive of disease course and response to immunotherapy^{22,23}. CBA is also widely used for scientific research. For example, Yang et al.²⁴ described the clinical features of anti-AQP4 IgG-positive NMOSD patients. Additionally, Kitley et al.²⁵ analyzed the prognostic factors for anti-AQP4 IgG-positive NMOSD patients²⁵. Both studies used CBA to detect serum anti-AQP4 IgG.

In summary, CBA is a widely used method to detect anti-AQP4 IgG and can be applied to clinical diagnosis and scientific research of NMOSD.

ACKNOWLEDGMENTS:

The authors are grateful for the support from grants from the National Science Foundation of China (No. 31600820), The Health and Family Planning Commission of Jilin Province (No. 2016Q036), and The Science and Technology Planning Project of Jilin Province (No. 20180520110JH).

DISCLOSURES:


The authors have nothing to disclose.

REFERENCES:


1. Zekeridou, A., Lennon, V. A. Aquaporin-4 autoimmunity. *Neurology Neuroimmunology & Neuroinflammation*. **2** (4), e110, 10.1212/NXI.0000000000000110 (2015).

2. Ho, J. D. et al. Crystal structure of human aquaporin 4 at 1.8 Å and its mechanism of conductance. *Proceedings of the National Academy of Sciences of the United States of America*. **106** (18), 7437-7442, 10.1073/pnas.0902725106 (2009).
3. Takeshita, Y. et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. *Neurology Neuroimmunology & Neuroinflammation*. **4** (1), e311, 10.1212/NXI.0000000000000311 (2016).
4. Sato, D. K. et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. *Neurology*. **82** (6), 474–481, 1212/WNL.0000000000000101 (2014).
5. Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. **85** (2), 177–89, 10.1212/WNL.00000000000001729 (2015).
6. Ruiz-Gaviria, R. et al. Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: A meta-analysis. *Multiple Sclerosis and Related Disorders*. **4** (4), 345-349, 10.1016/j.msard.2015.06.003 (2015).
7. Waters, P. et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. *Journal of Neurology, Neurosurgery, and Psychiatry*. **87** (9), 1005-1015, 10.1136/jnnp-2015-31260 (2016).
8. Fryer, J. P. et al. AQP4 autoantibody assay performance in clinical laboratory service. *Neurology Neuroimmunology & Neuroinflammation*. **1** (1), e11, 10.1212/NXI.0000000000000011 (2014).
9. Long, Y. et al. Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China. *The International Journal of Neuroscience*. **127** (9), 790-799, 10.1080/00207454.2016.1259226 (2017).
10. Pisani, F. et al. Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. *PloS One*. **8** (11), e79185, 10.1371/journal.pone.0079185 (2013).
11. Jarius, S. et al. Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. *Journal of Neuroinflammation*. **11**, 129, 10.1186/1742-2094-11-129 (2014).
12. Juryńczyk, M., Craner, M., Palace, J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. *Journal of Neurology, Neurosurgery, and Psychiatry*. **86** (1), 20-25, 10.1136/jnnp-2014-308984 (2015).
13. Chen, H. et al. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. *Chinese Medical Journal*. **129** (17), 2079-2084, 10.4103/0366-6999.189046 (2016).
14. Majed, M., Fryer, J. P., McKeon, A., Lennon, V. A., Pittock, S. J. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. *Neurology Neuroimmunology & Neuroinflammation*. **3** (3), e231, 10.1212/NXI.0000000000000231 (2016).
15. Jarius, S. et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. *Journal of Neuroinflammation*. **7**, 52, 10.1186/1742-2094-7-52 (2010).
16. Asgari, N. et al. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. *Neurology Neuroimmunology & Neuroinflammation*. **4** (4), e343, 10.1212/NXI.0000000000000343 (2017).
17. Kim, H. J. et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. *Neurology*. **84** (11), 1165-1173, 10.1212/WNL.0000000000001367 (2015).


18. Jarius, S. *et al.* MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. *Journal of Neuroinflammation*. **15** (1), 134, 10.1186/s12974-018-1144-2 (2018).
19. Narayan, R. *et al.* MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. *Multiple Sclerosis and Related Disorders*. **25**, 66-72, 10.1016/j.msard.2018.07.025 (2018).
20. Ogawa, R. *et al.* MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. *Neurology Neuroimmunology & Neuroinflammation*. **4** (2), e322, 10.1212/NXI.0000000000000322 (2017).
21. Valentino, P., Marnetto, F., Granieri, L., Capobianco, M., Bertolotto, A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. *Neurology Neuroimmunology & Neuroinflammation*. **4** (2), e317, 10.1212/NXI.0000000000000317 (2016).
22. Kessler, R. A. *et al.* Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. *Multiple Sclerosis and Related Disorders*. **17**, 198-201, 10.1016/j.msard.2017.08.005 (2017).
23. Mealy, M. A. *et al.* Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. *Multiple Sclerosis*. 1352458517730131, 10.1177/1352458517730131 (2017).
24. Yang, Y. *et al.* The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. *Journal of Clinical Neuroscience*. **20** (1), 94-98, 10.1016/j.jocn.2012.06.006 (2013).
25. Kitley, J. *et al.* Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. *Brain*. **135** (6), 1834-1849, 10.1093/brain/aww109 (2012).




A Top view of reagent tray



B Top view of biochip slide




C Front view of reagent tray and biochip slide




Transfected areas of negative control


4X





10X




20X










Untypical negative sample (10X)

Transfected area

Untransfected area



Magnification	Transfected area	Untransfected area
4X	1 picture	1 picture
10X	4 pictures	1 picture
20X	5 pictures	1 picture

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Anti-aquaporin-4 IIFT	Euroimmun	FA 1128-2005-50	Contains biochip slides coated with A
CellSens Dimension	OLYMPUS	N/A	photograph software
Gel & clot activator tube	Improve medic	623040202	From a local Chinese company

QP4-M1 transfected and untransfected EU 90 cells, fluorescein-labelled anti-human IgG, anti-AQP4 a

antibody as positive control, antibody negative sample, salt for PBS pH 7.2, Tween 20 and embedding

medium.



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Human serum anti-aquaporin-4 antibody detection by cell-based assay

Author(s):

Caiyun Liu, Mingqin Zhu, Ying Wang

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Ying Wang		
Department:	Department of Neurology and Neuroscience Center		
Institution:	The First Hospital of Jilin University		
Title:	Dr.		
Signature:		Date:	2018-08-28

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

The **JOVE** Editorial Board

Re: Revised manuscript

Oct 9th, 2018

Dear Prof. Steindel,

Thank you for all the efforts concerning our manuscript entitled “**Human serum anti-aquaporin-4 immunoglobulin G detection by cell-based assay**”. The comments from the reviewers have been most helpful in the revision of our manuscript. We have dealt fully with the comments from the reviewers and revised our manuscript accordingly, which is now re-submitted. We have specified the changes made in the manuscript (underlined), as well made point-to-point responses to the comments from the reviewers as follows:

Response to editorial comments

“Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.”

Thank you for the comment. We have proofread the manuscript carefully to avoid typos and grammar issues.

“Please remove commercial language from the manuscript: Euroimmun, Tween, CellSens, etc. Please replace them with generic terms.”

All the commercial language in the manuscript has been removed. However, as Tween is a chemical name instead of commercial name, it is not excluded.

“Please revise the protocol to contain only action items that direct the reader to do something (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a “Note.” Please include all safety procedures and use of

hoods, etc. However, notes should be used sparingly and actions should be described in the imperative tense wherever possible.”

The manuscript has been revised accordingly.

“1.1: Please write the text in the imperative tense.”

The statement has been revised accordingly (line 77).

“2.1.2, 2.4.1: Please list an approximate volume of buffer to be prepared.”

The volume of buffer has been added to the protocol accordingly (line 111 and 138).

“Please provide the concentration of antibodies used in the protocol.”

The manuscript has been revised accordingly (line 113 and 132).

“Please include single-line spaces between all paragraphs, headings, steps, etc.”

We have made sure to use single-line space.

“After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.”

The part of protocol for shooting has been highlighted.

“Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.”

The protocol has been highlighted accordingly.

“Figures 3-7, Table 1: Please use a capital X to denote magnification. There should be no space between the number and the X (i.e., 4X, 10X, 20X).”

Thank you for the suggestion. The table and figures have been revised accordingly.

“References: Please do not abbreviate journal titles.”

All the references have been revised.

“ Please revise the table of the essential supplies, reagents, and equipment to include the name, company, and catalog number of all relevant materials including software.”

The table has been revised accordingly.

“Table of Equipment and Materials: Please provide lot numbers and RRIDs of antibodies, if available.”

The antibodies are included in the kit and the lot number is not available.

Response to comments from Reviewer #1

“The protocol, line 101, the authors stated a wide range of the temperature for storing sera to maintain the stability of the samples. It would be great to specify the different acceptable periods of sera to store under -20 and -80 °C, for example, storage at ambient is acceptable for 72 hours, storage at -20 °C is acceptable to keep for months, and -80 °C is acceptable to keep for years.”

Thank you for the suggestion. The protocol has been revised accordingly (line 100).

“The protocol, line 118, it was good that the authors noted "Do not touch the BIOCHIPS". Handling the slides before removing from the cover, for instance, holding the slide side by side, is also important and should be addressed.”

This important tip has been added (line 118).

“The protocol, line 133, please review and confirm that it is necessary to cover the slides by dark box or foil. The advantage of the EUROIMMUN kit is it is unnecessary to cover the slides after adding secondary antibody.”

The referred protocol has been modified (line 136).

“The protocol, line 138, it is recommended and practical to drop the mounting medium onto a

cover glass rather than directly adding onto the BIOCHIPS. Then put the BIOCHIPS facing downwards onto the prepared cover glass.”

Thank you for the comment. As the BIOCHIPS should face upwards for microscopy, it is more convenient to add mounting medium directly onto the BIOCHIPS. It works well.

“Discussion, line 234, multiple sclerosis so far is not proven to be exactly an autoimmune disease. Either immune-mediated or inflammatory disease would be appropriated in this context.”

The description has been modified accordingly (line 236).

“Discussion, line 257-259, the statement authors mentioned is true for the "probable positive" result. Such a problematic result is difficult to judge. One possible solution would be repeating the CBA again.”

Thanks for the suggestion. The solution has been mentioned in the discussion section (line 259).

Response to comments from Reviewer #2

Reviewer #2:

“As the authors use the Euroimmun chip (from a commercial entity) it is unclear if the authors simply follow the manufacturer's instructions or have developed the implementation on their own. Thus, it is unclear if there are any IP/copyright issues.”

Thank you for the comment. We have confirmed with editor that it shouldn't be a problem more or less following manufacturer's instructions. Firstly, although their BIOCHIP is special, the protocol, which is a widely used immunocytochemistry protocol, is not special. Such as ELISA, Western blot and cell culture protocols, everybody has a basic idea on how to perform the experiment. It is hard to avoid that some details need to be adapted to the instruction given by the distributor. Secondly, we do not simply follow the instruction, we have optimized and re-arranged the protocol.

“The paper needs to be seen by a native speaker.”

Typos and grammar errors have been carefully corrected.

“In how many patients and controls was the protocol validated? Was the assay compared with another detection method? How many false positives/false negatives have the authors detected?”

The detection has been performed on approximately 1,500 subjects (line 74). The assay was not compared with other detection methods. However, the conclusions from relevant comparison studies were summarized in introduction and discussion section.

“Several pertinent references are neglected or inappropriate. First sentence of the introduction: PMID: 26185772 applies here; “Anti-AQP4 is involved....” PMID: 28018943 applies here; Discussion/MRI findings: PMID: 28451627 and PMID: 25695963 apply here; Discussion: mention that testing for AQP4 abs in the CSF is not informative, see PMID: 27144221, PMID: 20825655; Discussion/MOG: different clinical phenotype and some recent work deserves mention, see PMID: 29724224, PMID: 30048919, PMID: 28105459; Discussion: mention titers may change with rituximab PMID: 28054001; Discussion: titers not predictive of disease course and response to immunotherapy, see and add PMID: 29055457, PMID: 28857723”

Thank you for the comments. The referred parts of manuscript have been revised and the references have been updated (line 37, 42, 269, 261, 270 and 272).

““Sven et al. reported....” It must be “Jarius et al....”

Thank you for the comment. The error has been corrected (line 64).

“1.1.1. optic neuritis: testing in any case is not recommended as the pre-test probability in an unselected cohort is low, see PMID: 20850793”

Thank you for the comment. The description has been modified (line 80).

“2.5.1 any technical requirements for the microscope?”

No special requirement is for the microscope.

“blindly evaluated by at least 2 clinicians” any comment on the required experience of the grader?”

The required experience of clinicians has been added (line 176).

“table 2: how many sera from nmo and other conditions/hc have the authors tested with this method?”

As our detection is for diagnosis instead of for scientific researches, we do not perform titer analysis of anti-AQP4 IgG. We realized that the method was not verified by our diagnostic center. Table 2 and relevant description have been deleted.